The global Sintilimab market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Sintilimab is a fully human IgG4 monoclonal antibody medication that binds to programmed cell death protein 1 for the treatment of Hodgkin’s disease. The major factor attributing to the growth of the global sintilimab market is the rising prevalence of Hodgkin’s disease across the globe. According to the American Society of Clinical Oncology (ASCO), around 83,087 people were diagnosed with Hodgkin’s disease also called Hodgkin lymphoma globally with a mortality of around 23,376 people around the globe. Estimation of around 85,40 people will be diagnosed with Hodgkin lymphoma in the US alone in 2022 including 4,570 men and 3,970 women. Hodgkin lymphoma can affect both children and adults, particularly people in their 20s and people aged over 55 years.
In addition, several developments and approvals from The US Food and Drug Administration (FDA) are further contributing to the growth of the global sintilimab market. For instance, in May 2021, The USFDA approved a biologics license application (BLA) for sintilimab in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with nonsquamous non-small-cell lung cancer (NSCLC). This decision was taken after the results of phase-3 clinical trials. Similarly, in June 2021, Innovent Biologics got approval from the national medical products administration (NMPA) of China for the use of TYVYT, a sintilimab injection in combination with BYVASDA, a bevacizumab biosimilar injection as the first-line therapy for the treatment of hepatocellular carcinoma.
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers, acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Innovent Biologics in partnership with Eli Lilly & Co. announced the expansion of their strategic alliance of TYVYT. TYVYT is a sintilimab injection, an anti-PD-1 monoclonal antibody immune-oncology medicine that can be used for the treatment of Hodgkin lymphoma and co-developed by Innovent Biologics and Eli Lilly & Co. in China.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Sintilimab Market at: https://orionmarketreports.com/request-sample/?id=100768&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- By End-user
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Teva Pharmaceuticals Industries Ltd., Viatris Inc., Sun Pharmaceuticals Ltd., Eli Lilly & Co., and Innovent Biologics (Suzhou) Ltd., among others.
A full report Sintilimab Market of is available at: https://orionmarketreports.com/sintilimab-market/100768/
Global Sintilimab Market Report by Segment
By Application
- Children
- Adults
- Old-aged
By End-user
- Hospitals
- Speciality Clinics
- Others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
